News

UBS has told investors that the recent slide in AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) shares has gone too far, keeping its buy rating on the FTSE 100 drugmaker even after two clinical setbacks and speculation about a mega-merger. The stock has fallen roughly 15% since early July, when two...

LB Pharmaceuticals is on a tear. The IPO stock has more than tripled as investors watch its efforts in neuropsychiatric disorders.

Novartis’ latest trial setback serves a cautionary tale for investors betting on big pharma’s strategy of making bite-size acquisitions to bolster their drug pipelines. In theory, smaller deals offer big pharma access to promising and potentially lucrative drugs without the risk inherent in big bets.

Trial freezes by Novartis and Bristol Myers have triggered a race to understand why a promising autoimmune treatment turned risky.

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Novartis paused eight clinical trials of an experimental therapy targeting autoimmune and neurological disorders in late August, after three patients died.

Seaport Therapeutics just went public with a prodrug platform that has attracted board members from two of the biggest neuroscience acquisitions in recent history. The question is whether the same giants who funded those deals are already circling for a third.

Pharmaceutical chiefs are always hunting for drugs to replace expiring blockbusters. But shopping while hungry can lead to expensive mistakes.

Companies try to get deals done while regulators allow them. But are buyouts always a good idea?

There's a good reason why AstraZeneca tanked when merger rumors hit the Street.

AbbVie's growth engine is firing on all cylinders, but on its latest earnings call, analysts focused on whether the company can defend its turf and execute on its next big pipeline bet.

One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly £4.5bn deal to buy the theatre group behind West End venues including...

For years, healthcare and semiconductor stocks weren’t particularly tied to each other. In other words, they increasingly go in opposite directions: when chips sell off, healthcare has tended to catch a bid. After years of underperformance, healthcare investors are enjoying a burst of momentum amid the recent nervousness around AI.

Surging oil prices, a CPI spike not seen in three years, and Treasury yields at levels last touched in 2007 are forcing a September rate decision that could reshape which stocks lead the market through the rest of 2026.

10x Genomics reported second-quarter revenue of $151 million, including $1.6 million in license and royalty revenue tied to its settlement with Takara Bio. Excluding non-recurring settlement revenue in both periods, revenue was $149.4 million, up 3% from the prior-year quarter. Chief Executive Offi

CYTK tops Q2 revenue estimates as Myqorzo gains traction, but higher launch costs and the absence of milestone payments weigh on results.

Few big-pharma bosses enjoy a stronger reputation on Wall Street than AstraZeneca’s chief executive, Pascal Soriot. After plunging on a Financial Times report of merger discussions with Bristol-Myers Squibb shares of AstraZeneca recovered somewhat when Reuters reported there are no ongoing talks. After rebuffing Pfizer’s $120 billion takeover bid in 2014, he steadily transformed AstraZeneca into one of the drug industry’s top growth stories.

Reports of talks were quickly disputed, but the prospect exposed the appeal — and antitrust risks — of combining two pharma giants.

Schrodinger (NASDAQ:SDGR) said second-quarter annual contract value growth accelerated as demand broadened across large pharmaceutical customers, biotechnology companies and materials-science customers, while the company launched early access for Bunsen, its agentic AI co-scientist. Second-quarter

Braveheart is one of five biotechnology firms that made plans to price an IPO this week, bringing in total what could ultimately be more than $1 billion from public investors.

📣"I don't know the needs of the two competitors that are right now trying to talk to each other, but we don't see a need for a transformative M&A right now." —Mike Doustdar, CEO of Ozempic maker Novo Nordisk in an interview with the Journal, referring to a recent Financial Times report that AstraZeneca and Bristol Myers Squibb held talks over a tie-up.

According to a Reuters report, a senior source denied merger discussions between AstraZeneca and Bristol Myers Squibb.

Aug 5 (Reuters) - There are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb over a ‌potential deal, a senior source close to the matter told ‌Reuters on Wednesday, quashing the prospect of a mooted mega merger between the drugmakers. "There ​is no deal between AstraZeneca and BMS.

A source close to the matter told Reuters there is "no deal" and there "never was a deal to be done" between the two drugmakers

Chief Executive Mike Doustdar’s comments come amid sector focus on M&A and after Novo Nordisk made two disclosures in recent days on its future pipeline that disappointed investors.

Two of the world's biggest drugmakers moved in opposite directions on Monday, and the split says a lot about how Wall Street reads a merger. Reports surfaced over the weekend that AstraZeneca (AZN) had held talks about combining with Bristol Myers Squibb (BMY). The deal would be worth close ...

Citi has told clients that a large chunk of deal risk is already in AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) share price after Monday's sharp fall, while Deutsche Bank sees clear parallels with the drugmaker's Alexion acquisition five years ago. The two notes are the second-day response to a...

BioNTech (NASDAQ:BNTX) reported second-quarter 2026 revenue of €106 million, down from €261 million a year earlier, as lower U.S. demand for its COVID-19 vaccine weighed on results. The prior-year quarter also benefited from a one-time compensation payment from Pfizer related to its decision to opt

Even if a megamerger fails to materialize, investors stand to benefit from a wave of M&A activity in the biopharma sector.

Big drug companies have been buying scrappy biotechs to expand their pipelines, but the potential megamerger between AstraZeneca and Bristol Myers Squibb could flip that script.